Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Longo
P Lockhart

Showing results (171-180 of 194) with videos related to

Pageof 20
Sort By:
Vaccine|April 13, 2024
Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and olderMotoharu Yonekawa, Tohru Watanabe, Osamu Kogawara, et al.
Archives of Otolaryngology (Chicago, Ill. : 1960)|April 1, 1984
Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexateT J Ervin, R R Weichselbaum, R L Fabian, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Nature Chemical Biology|July 19, 2017
Structures of carboxylic acid reductase reveal domain dynamics underlying catalysisDeepankar Gahloth, Mark S Dunstan, Daniela Quaglia, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|June 4, 2016
Subunit Arrangement in GpsB, a Regulator of Cell Wall BiosynthesisRobert M Cleverley, Jeanine Rismondo, Michael P Lockhart-Cairns, et al.
Open Forum Infectious Diseases|May 25, 2026
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and OlderGretchen Crook, Erik Lamberth, Stephen P Lockhart, et al.
Neurology|November 27, 2002
SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findingsS Furtado, M Farrer, Y Tsuboi, et al.
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Pageof 20

Showing results (171-180 of 194) with videos related to

Sort By:
Pageof 20
Vaccine|April 13, 2024
Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and olderMotoharu Yonekawa, Tohru Watanabe, Osamu Kogawara, et al.
Archives of Otolaryngology (Chicago, Ill. : 1960)|April 1, 1984
Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexateT J Ervin, R R Weichselbaum, R L Fabian, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Nature Chemical Biology|July 19, 2017
Structures of carboxylic acid reductase reveal domain dynamics underlying catalysisDeepankar Gahloth, Mark S Dunstan, Daniela Quaglia, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|June 4, 2016
Subunit Arrangement in GpsB, a Regulator of Cell Wall BiosynthesisRobert M Cleverley, Jeanine Rismondo, Michael P Lockhart-Cairns, et al.
Open Forum Infectious Diseases|May 25, 2026
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and OlderGretchen Crook, Erik Lamberth, Stephen P Lockhart, et al.
Neurology|November 27, 2002
SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findingsS Furtado, M Farrer, Y Tsuboi, et al.
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Pageof 20